| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LCT |
| Uniprot No | P09848 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | 218 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LCT(乳糖酶)重组蛋白的参考文献示例(文献为虚构，仅供格式参考)：
1. **《高效表达重组人乳糖酶LCT的毕赤酵母系统构建》**
- 作者：Zhang et al.
- 摘要：研究通过毕赤酵母表达系统优化重组人乳糖酶LCT的分泌表达，酶活性达1200 U/mg，显著提高乳糖水解效率，为工业化生产提供方案。
2. **《大肠杆菌中重组LCT的包涵体复性及功能分析》**
- 作者：Wang & Liu
- 摘要：探讨大肠杆菌表达重组LCT时包涵体形成问题，优化复性条件后获得高活性酶，并验证其在模拟肠道环境中的稳定性。
3. **《LCT重组蛋白缓解乳糖不耐症的动物实验研究》**
- 作者：Smith et al.
- 摘要：通过小鼠模型证明口服重组LCT可有效分解肠道乳糖，缓解腹泻症状，为乳糖不耐症治疗提供新策略。
4. **《基于结构设计的LCT突变体热稳定性提升》**
- 作者：Chen et al.
- 摘要：通过分子动力学模拟和定点突变改造LCT结构，获得热稳定性提高的突变体，在50℃下半衰期延长至8小时。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed、ScienceDirect等。)
LCT (lactase-phlorizin hydrolase), commonly known as lactase, is a digestive enzyme responsible for hydrolyzing lactose into glucose and galactose. In humans, lactase activity declines after infancy in most populations, leading to lactose intolerance. Recombinant LCT proteins, produced via genetic engineering, have emerged as a solution to address this widespread condition.
The development of recombinant LCT leverages heterologous expression systems, such as yeast (e.g., *Kluyveromyces lactis*), fungi (e.g., *Aspergillus*), or bacteria (e.g., *E. coli*). These systems are optimized for high-yield enzyme production while maintaining functional stability. Compared to animal-derived lactase, recombinant versions offer advantages like scalability, reduced allergenicity, and ethical sourcing.
Commercial applications focus primarily on dietary supplements and food processing. Lactase-treated dairy products (e.g., lactose-free milk) dominate the market, catering to lactose-intolerant individuals. Additionally, recombinant LCT is used in industrial biotechnology for lactose hydrolysis in whey processing, reducing waste and enhancing product value.
Research continues to refine enzyme thermostability and activity across pH ranges to improve compatibility with diverse food matrices. Recent advances include immobilization techniques for reusable enzymatic systems and gene-editing approaches to enhance microbial production efficiency.
Despite progress, challenges persist, such as cost-effective large-scale fermentation and regulatory hurdles for novel expression hosts. Ongoing studies also explore therapeutic potential, including oral enzyme replacement therapies and synbiotic formulations with probiotics.
Overall, recombinant LCT exemplifies the intersection of biotechnology and public health, addressing a global nutritional issue while demonstrating the versatility of engineered enzymes in modern industry.
×
